Related Experiment Videos
Iron supplementation in haemodialysis--practical clinical guidelines
Summary
Intravenous iron supplementation effectively treats iron deficiency in haemodialysis patients, improving hemoglobin levels. Individualized ferritin targets are recommended over transferrin saturation or low ferritin levels for monitoring.
Area of Science:
- Nephrology
- Hematology
- Clinical Nutrition
Background:
- Iron deficiency is prevalent in haemodialysis patients despite oral supplementation.
- Assessing iron metabolism markers and target values is crucial for effective treatment.
Purpose of the Study:
- To evaluate a new intravenous iron supplementation protocol for haemodialysis patients.
- To determine the utility of various iron metabolism markers for correcting iron deficiency.
Main Methods:
- Prospective study of 33 haemodialysis patients over 6 months.
- Intravenous iron therapy administered at 20 mg thrice weekly post-dialysis.
- Inclusion criteria: %TSAT <20%, %HypoE >10%, or SF <400 microg/l; exclusion criteria: active infections, inflammatory or hematological diseases, psychosis, or iron overload.
Main Results:
- Over half of patients had iron deficiency.
- Mean hemoglobin increased from 10.8 to 12.8 g/dl (P<0.0001).
- Erythropoietin use decreased; ferritin <400 microg/l showed the best sensitivity/specificity (100/87.9%) for iron supplementation.
Conclusions:
- Intravenous iron supplementation is recommended for haemodialysis patients.
- Individualized ferritin targets are advised; mean hemoglobin peaked at 6 months with a mean ferritin of 456 microg/l.
- %TSAT, %HypoE, and ferritin <100 microg/l are not ideal for monitoring routine iron therapy.